Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/IIa trial of docetaxel plus ribavirin for reprogramming efficacy in patients with progressive metastatic castration resistant prostate cancer who have previously received docetaxel alone

Next Previous
X
Search
Trial Profile

A phase I/IIa trial of docetaxel plus ribavirin for reprogramming efficacy in patients with progressive metastatic castration resistant prostate cancer who have previously received docetaxel alone

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ribavirin (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Acronyms DRREEM
  • Sponsors Chugai Pharmaceutical

    • Most Recent Events

    • 10 Feb 2018 Results (n=6) presented at the 2018 Genitourinary Cancers Symposium.
    • 28 Dec 2016 Status changed from recruiting to completed.
    • 24 May 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top